First Tracks Biotherapeutics Announces Positive Phase 1b Clinical Results for Celiac Disease Treatment
TRAX First Tracks Biotherapeutics Inc
$34.13 +7.73%
View chart & analysis → - 1First Tracks Biotherapeutics shares rose 20% on Monday.
- 2In the first cohort of the Phase 1b trial, 47% of the placebo group required symptom-relieving medication.
- 3First Tracks Biotherapeutics plans to begin late-stage clinical trials for celiac disease in 2027.
So what's the key point?
First Tracks Biotherapeutics obtained positive results from its celiac disease treatment trial. The stock price rose 20% following this news.
Source InvestorsHub +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.